Bone health in postmenopausal women (PMW) with hormone-sensitive breast cancer (HSBC) receiving adjuvant aromatase inhibitor (AI) therapy

被引：2
|
作者：
Kalder, M. [1 ]
Hadji, P. [1 ]
机构：
[1] Univ Marburg, Marburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.11556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11556
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
    Catherine Van Poznak
    Breast Cancer Research, 12
  • [42] Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
    Dieter Koeberle
    Beat Thuerlimann
    Breast Cancer Research and Treatment, 2008, 112 (2) : 387 - 387
  • [43] The psychological consequences after adjuvant aromatase inhibitor therapy in breast cancer women
    Bianchi, E.
    Bosisio, M.
    Capri, G.
    Mariani, P.
    Miceli, R.
    Borreani, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer
    Petit, Thierry
    Dufour, Patrick
    Tannock, Ian
    ENDOCRINE-RELATED CANCER, 2011, 18 (03) : R79 - R89
  • [45] Aromatase inhibitors: Effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer
    Mauriac, Louis
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 20 : S15 - S29
  • [46] Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer
    Younis, T.
    Rayson, D.
    Dewar, R.
    Skedgel, C.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 293 - 298
  • [47] Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
    Pedersini, Rebecca
    di Mauro, Pierluigi
    Amoroso, Vito
    Castronovo, Vincenza
    Zamparini, Manuel
    Monteverdi, Sara
    Laini, Lara
    Schivardi, Greta
    Cosentini, Deborah
    Grisanti, Salvatore
    Marelli, Sara
    Strambi, Luigi Ferini
    Berruti, Alfredo
    BREAST, 2022, 66 : 162 - 168
  • [48] CHANGES IN BONE DENSITY OVER 1 YEAR OF AROMATASE INHIBITOR THERAPY IN WOMEN WITH POSTMENOPAUSAL BREAST CANCER AND OSTEOPENIA
    Taxel, Pamela
    Bansal, Renu
    Mirza, Faryal
    Hawli, Yousra
    Tannenbaum, Susan
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S220 - S220
  • [49] Postmenopausal breast cancer, aromatase inhibitors, and bone health
    Heneghan, H. M.
    McKenna, M.
    Walshe, J.
    Rothwell, J.
    Evoy, D.
    Geraghty, J.
    McDermott, E.
    Prichard, R. S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : 416 - 417
  • [50] Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)
    Brufsky, A.
    Lund, K.
    Papish, S.
    Cobb, R.
    Eisenberg, P.
    Dong, M.
    Warsi, G.
    Lacerna, L.
    Perez, E.
    BREAST, 2007, 16 : S57 - S57
12345